RxDoctor Payments Data

Nathan Boss, MD

Sleep Medicine · Charlevoix, MINPI 1699794958

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $34,950 of the $43,092 with a category attached, or 81.1%. Harmony Biosciences LLC accounts for 94.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $17,155 and has fallen 92.4% since, to $1,297 in 2025. Among sleep medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$43,092in general payments, 2019–2025

Across 61 payments — averaging $706.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$41K
  • Noctrix Health, Inc.$1K
  • Inspire Medical Systems, Inc.$785
  • Resmed Corp$67
  • AbbVie$20
  • Lilly USA, LLC$19
  • plus $16 from 1 others

What the payments were for

  • Consulting fees$3,6008%
  • Speaking & faculty fees$34,95081%
  • Travel & lodging$2,1785%
  • Food & beverage$2,3645%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,092 in reported general payments places this provider in the 95th percentile of 78 sleep medicine providers in Michigan.

See all sleep medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$21,687
Medicare patients
167
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl26$200,779
Armodafinil16$1,054
Fluticasone Propionate58$687
Trazodone Hcl50$664
Gabapentin59$650
Temazepam13$536
Ipratropium Bromide14$434
Azelastine Hcl26$397
Methylphenidate Hcl22$337
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$225
Mirtazapine16$218
Clonazepam17$155
Zolpidem Tartrate14$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$40,907$200,77926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 78 sleep medicine providers in Michigan.

Other sleep medicine in Charlevoix

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →